NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a corporate overview at the Barclays Global Healthcare Conference on Thursday, March 15, 2018, at 11:15
- Plans for clinical data in C3 glomerulopathy (C3G) and for paroxysmal nocturnal hemoglobinuria (PNH) remain on track for 2018 - - Joseph Truitt appointed Chief Executive Officer - NEW HAVEN, Conn., May 02, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 04, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43 rd Annual Health Care Conference on Tuesday, May 8,
- Oral presentation discussing ACH-4471 and interim biomarker data from the ongoing 14-day Phase 2 study in C3G - - Poster presentation detailing in vitro data showing no significant reduction in serum bactericidal activity with factor D inhibition - NEW HAVEN, Conn.
NEW HAVEN, Conn. , June 14, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt , President and Chief Executive Officer of Achillion, will present at the 2018 JMP Securities Life Sciences Conference on Thursday, June 21, 2018 , at 9:00 a.m.
- Additional clinical compounds expand factor D portfolio opportunities - NEW HAVEN, Conn. , July 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a clinical-stage pharmaceutical company focused on developing small molecule inhibitors of factor D in the complement
- Global phase 2 clinical programs for ACH-4471 continue to expand in PNH and C3G - - Completed dosing phase 1 clinical study of ACH-5228 and initiated phase 1 study of ACH-5548 - - June 30, 2018 cash position $295.8 million - NEW HAVEN, Conn. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Achillion
NEW HAVEN, Conn. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Anthony S. Gibney to the position of Executive Vice President and Chief Business Officer, effective immediately. Mr.
NEW HAVEN, Conn. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Steven Zelenkofske , D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. Dr.
NEW HAVEN, Conn. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt , President and Chief Executive Officer of Achillion, will present at the Baird 2018 Global Healthcare Conference on Thursday, September 6th, 2018 , at 9:05 a.m.